Immunohistochemical analysis of cyclin-dependent kinase inhibitor 1C (CDKN1C, p57, Kip2) expression and molecular genotyping accurately classify hydatidiform moles into complete and partial types and distinguish these from non-molar specimens. Characteristics of a prospective series of all potentially molar specimens encountered in a large gynecologic pathology practice are summarized. Initially, all specimens were subjected to both analyses; this was later modified to triage cases for genotyping based on p57 results: p57-negative cases diagnosed as complete hydatidiform moles without genotyping; all p57-positive cases genotyped. Of the 678 cases, 645 were definitively classified as complete hydatidiform mole (201), partial hydatidiform mole (158), non-molar (272), and androgenetic/biparental mosaic (14); 33 were unsatisfactory, complex, or problematic. Of the 201 complete hydatidiform moles, 104 were p57-negative androgenetic and an additional 95 were p57-negative (no genotyping), 1 was p57-positive (retained maternal chromosome 11) androgenetic, and 1 was p57-non-reactive androgenetic; 90 (85%) of the 106 genotyped complete hydatidiform moles were monospermic and 16 were dispermic. Of the 158 partial hydatidiform moles, 155 were diandric triploid, with 154 p57-positive, 1 p57-negative (loss of maternal chromosome 11), and 1 p57-non-reactive; 3 were triandric tetraploid, with 2 p57-positive and 1 p57-negative (loss of maternal chromosome 11). Of 155 diandric triploid partial hydatidiform moles, 153 (99%) were dispermic and 2 were monospermic. Of the 272 non-molar specimens, 259 were p57-positive biparental diploid, 5 were p57-positive digynic triploid, 2 were p57-negative biparental diploid (no morphological features of biparental hydatidiform mole), and 6 were p57-non-reactive biparental diploid. Of the 14 androgenetic/biparental mosaics with discordant p57 expression, 6 were uniformly mosaic and 8 had a p57-negative androgenetic molar component. p57 expression is highly correlated with genotyping, serves as a reliable marker for diagnosis of complete hydatidiform moles, and identifies androgenetic cell lines in mosaic conceptions. Cases with aberrant and discordant p57 expression can be correctly classified by genotyping.
non-molar specimens is important for appropriate clinical management, as a diagnosis of partial hydatidiform mole generates follow-up with serum beta human chorionic gonadotropin (HCG) levels and contraception, which would be unnecessary following a diagnosis of a non-molar specimen and undesirable for infertility patients. However, previous studies have demonstrated that diagnosis of hydatidiform moles based on morphology alone, even by experienced pathologists with specialized training, is subject to interobserver variability and therefore suboptimal diagnostic reproducibility. [9] [10] [11] [12] [13] [14] [15] A number of studies have demonstrated the value of ancillary techniques, including immunohistochemical analysis of cyclin-dependent kinase inhibitor 1C (CDKN1C/p57/Kip2, the protein product of the CDKN1C imprinted gene located at chromosome 11p15.5; referred to henceforth as p57) expression [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] and molecular genotyping via PCR amplification of short tandem repeat loci, 23, 25, [28] [29] [30] [31] for improving the diagnosis of hydatidiform moles. Genotyping is particularly valuable because it allows for specific distinction of complete hydatidiform moles, partial hydatidiform moles, and nonmolar specimens from one another due to their unique genetics. Complete hydatidiform moles are purely androgenetic and usually diploid (two paternal chromosome complements without a maternal chromosome complement), 32 with most resulting from fertilization of an egg by a single sperm that duplicates (monospermy) 33, 34 and a minority via fertilization by two sperms (dispermy), 35 with loss of the maternal chromosome complement. In contrast, partial hydatidiform moles are characterized by diandric triploidy (two paternal and one maternal chromosome complements), with most arising by dispermy. [36] [37] [38] Non-molar specimens are usually characterized by biparental diploidy (one paternal and one maternal chromosome complements). Some non-molar specimens are digynic triploid conceptions (two maternal and one paternal chromosome complements) but do not exhibit molar features, 39 with the exception of rare examples having the morphology and immunophenotype (p57-negative) of complete hydatidiform moles occurring in patients with familial recurrent hydatidiform mole associated with mutations in NLRP7 (NALP7) or KHDC3L (C6orf221). 40 In addition, some non-molar specimens with cytogenetic abnormalities such as trisomy can simulate partial hydatidiform moles, causing problems in diagnostic reproducibility. 41, 42 In 2007, we began a prospective analysis of all potentially molar products of conception specimens encountered on the Gynecologic Pathology Service of The Johns Hopkins Hospital, Baltimore, MD using immunohistochemical analysis of p57 expression and molecular genotyping with short tandem repeat markers. 25, 31, 43 The current study summarizes the results of nearly 6 years of analysis, providing a summary of the characteristics of a large series of hydatidiform moles and non-molar specimens assessed by these techniques as well as the assessment of the performance of these methods in clinical practice.
Materials and methods
All cases encountered on the Gynecologic Pathology Service of The Johns Hopkins Hospital, Baltimore, MD for which there was any clinical or pathological concern for a molar specimen were prospectively analyzed according to the diagnostic algorithm shown in Figure 1 . From July 2007 through March 2013, 678 cases were analyzed, with 86% representing consultation cases and 14% representing routine in-house cases. Initially, all specimens were subjected to both p57 immunohistochemical analysis and molecular genotyping with short tandem repeat markers. After sufficient experience with the reliability of p57 analysis for identifying androgenetic complete hydatidiform moles, this process was later modified to triage cases for genotyping based on p57 results. Thereafter, in the setting of appropriate morphology features, p57-negative cases were diagnosed as complete hydatidiform moles without genotyping and all p57-positive cases continued to be subjected to genotyping. 25, 31 In addition, any cases for which p57 immunohistochemical analysis was unsatisfactory were genotyped. In certain uncommon situations involving cases that had morphology and p57 results in our laboratory consistent with a diagnosis of complete hydatidiform mole but Figure 1 Algorithmic approach to diagnosis of hydatidiform moles. Potentially molar specimens were evaluated according to this process. Initially, all specimens were subjected to both p57 immunohistochemical analysis and molecular genotyping with short tandem repeat markers. Cases were diagnosed as complete hydatidiform moles when genotyping demonstrated androgenetic diploidy, as partial hydatidiform moles when genotyping demonstrated diandric triploidy, and as non-molar specimens when genotyping demonstrated biparental diploidy. This process was later modified to triage cases for genotyping based on p57 results, with p57-negative cases being diagnosed as complete hydatidiform moles without genotyping and all p57-positive cases being subjected to genotyping.
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N Banet et al outside ancillary testing suggesting a different diagnosis, genotyping was performed to confirm our results. These included cases for which outside laboratory testing reported a DNA index/ploidy result consistent with triploidy and cases in which some focal or apparently discordant p57 expression was noted on a p57 immunostain performed at an outside laboratory but was not seen on the p57 immunostain performed in our laboratory.
Immunohistochemical analysis of p57 expression was performed on 4-m formalin-fixed paraffinembedded sections, which were stained using a Ventana BenchMark XT automated immunostaining system (Tucson, AZ, USA) with mouse monoclonal antibodies against p57 protein (Neomarkers, Fremont, CA, USA) from a ready-to-use preparation without dilution. To interpret immunohistochemical stains for p57, the presence or absence of nuclear positivity was assessed in villous stromal cells, cytotrophoblast, intermediate trophoblast, and maternal decidua. The p57 immunostain was interpreted as 'negative' and satisfactory when maternal decidua and/or intermediate trophoblastic cells exhibited nuclear expression of p57 (serving as internal positive control in all the cases, including complete hydatidiform moles) but villous stromal cells and cytotrophoblast were either entirely negative or demonstrated only limited expression (nuclear staining in o10% of these cell types). This negative result was then interpreted as consistent with a diagnosis of a complete hydatidiform mole, provided the morphology of the specimen was appropriate. The p57 immunostain was interpreted as 'positive' when the extent of staining in these cell types was extensive or diffuse. Nuclear expression in villous stromal cells and cytotrophoblast in the focally positive range (Z10% but o50%) has been considered an 'equivocal' result in our previous studies, but when using a binary system of 'positive' and 'negative' for final interpretation these equivocal results are considered positive based on our experiences, indicating that these equivocal cases have never been confirmed as complete hydatidiform moles per genotyping. The p57 expression pattern was interpreted as 'discordant' when there was any combination/admixture of negative and positive results for villous stromal cells and cytotrophoblast within individual villi, including positive staining in cytotrophoblast and negative staining in villous stromal cells, or vice versa. Discordant p57 expression characterizes androgenetic/biparental mosaic/chimeric conceptions, with discordant expression in different cell types based on the presence or absence of maternal genetic material in those particular cells (described in detail in our recent study). 44 The p57 expression pattern was further interpreted as 'divergent' when two populations of villi, each with different morphologies, exhibited two different staining patterns, eg, a twin gestation comprised of a p57-negative androgenetic diploid complete hydatidiform mole and a p57-positive biparental diploid non-molar specimen or a mosaic specimen comprised of a p57-discordant non-molar specimen component and a p57-negative complete hydatidiform mole component.
Molecular genotyping was performed using unstained 10-m formalin-fixed paraffin-embedded tissue sections prepared using PCR precautions. A serial H&E-stained 4-m section was used to identify well-separated areas of maternal decidua and villous tissue. An area of each tissue type was circled with a marking pen on the H&E slide. An unstained slide was superimposed on top of the marked H&E slide and Pinpoint solution (Zymo Research, Orange, CA) was applied to the areas of interest. The tissue was removed from the slide and digested per the manufacturer's protocol. DNA was further purified using QIAamp DNA spin columns (Qiagen, Valencia, CA). PCR amplification of nine short tandem repeat loci from eight different chromosomes (chromosomes 2, 3, 4, 5, 7, 11, 12, 13) and the amelogenin locus (for XY determination) was performed, with thermal cycling conditions and capillary electrophoresis carried out according to the manufacturer's instructions (AmpFlSTR Profiler kit; Applied Biosystems; Foster City, CA). In certain selected situations (see results), an expanded analysis with PCR amplification of 15 short tandem repeat loci from 13 different chromosomes (chromosomes 2, 3, 4, 5, 7, 8, 11, 12, 13, 16, 18, 19, 21) and the amelogenin locus (for XY determination) was performed (AmpFlSTR Identifiler kit; Applied Biosystems). The PCR conditions were 95 1C for 11 min followed by 28 cycles of 94 1C for 1 min, 59 1C for 1 min, and 72 1C for 1 min, followed by a final extension at 60 1C for 45 min. After amplification, 1 ml of multiplex PCR product was mixed with 9 ml of deionized formamide/GeneScan 500 [ROX] size standard (Applied Biosystems). Samples were denatured at 95 1C for 2 min and placed on ice for at least 1 min before analysis (ABI3100 and ABI 3130xl Genetic Analyzers, Applied Biosystems). Capillary electrophoresis data were analyzed per criteria in our previously published validation study. 31 Both the maternal and villous tissues were analyzed to identify alleles at each locus. The villous tissue was further analyzed as follows. Every allele from the villous tissue was identified as being maternal, definitively non-maternal (assumed paternal), or equivocal (unknown whether maternal or paternal due to shared alleles) in origin. For each locus with two alleles identified, the allelic ratio was calculated by dividing the peak height of the longer allele by the peak height of the shorter allele. Allelic ratios between 0.61 and 1.17 were considered to be consistent with diploidy. Allelic ratios between 0.33 and 0.60 or 1.5 and 2.0 were considered to be consistent with triploidy. Loci with three alleles identified in a 1:1:1 ratio were also considered consistent with triploidy. The origin of triploidy was determined when possible based on combined evaluation of allele ratios and source for Modern Pathology (2014) 27, 238-254 Diagnosis of hydatidiform moles those alleles with sufficient polymorphism. Each locus was scored as being consistent with diploidy or triploidy or not informative. At least two informative loci were required for final interpretation. The complete hydatidiform moles subjected to genotyping were diagnosed as such by the finding of purely androgenetic alleles. The vast majority are characterized by androgenetic diploidy (two sets of paternal chromosome complements, without a maternal chromosome complement) but a small subset can have androgenetic tetraploidy (genotyping does not specifically distinguish diploid examples from tetraploid examples as peak heights do not indicate actual DNA content). Partial hydatidiform moles were diagnosed by the finding of diandric triploidy (three sets of chromosome complements, two paternal in origin and one maternal in origin (paternal:maternal allele ratio of 2:1)) or triandric tetraploidy (four sets of chromosome complements, with one maternal in origin and three paternal in origin (paternal:maternal allele ratio of 3:1)). Non-molar specimens, including those with abnormal villous morphology related to other non-molar genetic alterations such as trisomy, were diagnosed as such when the genotyping demonstrated biparental diploidy (one maternal and one paternal chromosome complement) and also when digynic triploidy (two maternal and one paternal chromosome complements) was identified, as these latter specimens do not have molar features and are not considered a form of hydatidiform mole. Mosaic/chimeric conceptions were diagnosed by the finding of p57-discordant staining patterns combined with genotyping demonstrating an excess of androgenetic alleles with variable paternal:maternal allele ratios Z2:1, indicating admixtures of androgenetic and biparental cell lines within individual villi (details provided in a recent study). 44 
Results
The study included a total of 678 cases. Diagnostic categorization of cases and age distribution are summarized in Table 1 . The mean and median ages for all diagnostic categories were similar (27-32 years); the small subset of invasive complete hydatidiform moles had older mean and median ages (39/42 years). Age ranges were similar for partial hydatidiform moles, non-molar specimens, and mosaic cases (13-46 years combined) but different for complete hydatidiform moles, with the age range for complete hydatidiform moles extending beyond age 46 years (up to 55 years). Thus, all patients aged 446 years had complete hydatidiform moles (n ¼ 22; mean/median ¼ 50/49.5 years, with 11 aged Z50 years).
All the 678 cases were subjected to p57 immunohistochemical analysis and 583 were subjected to genotyping per the algorithm (Figure 1 ). Detailed results of immunohistochemical analysis of p57 expression and genotyping are summarized in Tables 2 and 3 . Representative examples are illustrated in Figures 2-4 , with corresponding genotyping data presented in Figures 5-9 . In all, 665 of the 678 cases (98%) subjected to p57 immunohistochemical analysis had satisfactory p57 results (Table 2) , with 13 (2%) unsatisfactory (non-reactive) or suboptimal (limited weak/equivocal expression in the setting of suboptimal internal positive control) due to degenerative changes and/or technical factors. Also, 558 of the 583 cases (96%) subjected to genotyping yielded satisfactory results (Table 3) . Of the 652 cases (96%) for which successful diagnostic results were obtained by either immunohistochemical analysis and/or genotyping, 645 (99%) were definitively classified. These 645 cases were classified as complete hydatidiform mole in 201, as partial hydatidiform mole in 158, as non-molar specimen in 272, and as androgenetic/biparental mosaic in 14. The remaining 33 cases included 7 with complex genotypes that were not readily classifiable, 1 problematic case (discussed in more detail below), and 25 with unsuccessful genotyping analysis. In these 25 cases, unsuccessful genotyping was attributable to insufficient villi, villi being too intimately admixed with decidua for successful microdissection of pure tissue components, or a lack of decidua that precluded definitive interpretation Villous stromal cells and cytotrophoblast are diffusely positive for p57 (d), usually arguing against a diagnosis of a complete hydatidiform mole; however, genotyping demonstrated androgenetic diploidy with trisomy 11 due to a retained maternal copy (see Figure 6 ). (e-g). Partial hydatidiform mole is characterized by hydropic irregularly shaped villi with scalloped contours (e), trophoblastic inclusions (f), and mild circumferential trophoblastic hyperplasia (g). Villous stromal cells and cytotrophoblast are diffusely positive for p57 (h). Genotyping demonstrated diandric triploidy (see Figure 7 ).
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Diagnosis of hydatidiform moles sion of an additional 8 androgenetic/biparental mosaics with a molar (androgenetic complete hydatidiform mole) component raised the total molar cases to 367 (56%). All the 201 complete hydatidiform moles had p57 analysis and 106 were genotyped. Of the 201 complete hydatidiform moles, 104 were p57-negative androgenetic (Figures 2a and b, Figure 5 ) and an additional 95 were p57-negative (no genotyping), 1 was p57-positive androgenetic with aberrant p57 expression attributable to a retained maternal copy of chromosome 11 (location of the p57 gene) (Figures 2c, d , and 6), and 1 was p57-non-reactive androgenetic (technically unsatisfactory immunostain). Of the 106 genotyped androgenetic complete hydatidiform moles, 90 (85%) were monospermic (XX) and 16 (15%) were dispermic (13 XY, 3 XX) ( Table 4 ). The complete hydatidiform moles included four multiple gestations comprised of a p57-negative androgenetic diploid complete hydatidiform mole and p57-positive biparental diploid non-molar specimen (three twins, one quintuplet). There were seven invasive complete hydatidiform moles encountered in hysterectomy specimens. Of these, five were monospermic XX and two were dispermic XY, with the monospermic examples confirmed as such by analysis with the expanded panel of markers (Identifiler kit; Table 5 ). Three of the seven invasive complete hydatidiform moles had atypical trophoblastic proliferations morphologically consistent with choriocarcinoma. Of these, two were monospermic (XX) and one was dispermic (XY); one of each of these types had lung nodules consistent with metastatic gestational trophoblastic disease.
All the 158 partial hydatidiform moles had both p57 analysis and genotyping. Of the 158 partial hydatidiform moles, 155 were diandric triploid, with 154 p57-positive (Figures 2e-h, Figures 3a  and b, Figure 7 ), 1 p57-negative with loss of p57 expression attributable to loss of the maternal copy of chromosome 11 (Figures 3c and d, Figure 8 ), and 1 p57-non-reactive (technically unsatisfactory); 3 partial hydatidiform moles were triandric tetraploid, with 2 p57-positive and 1 p57-negative with loss of p57 expression attributable to loss of the maternal copy of chromosome 11. Based on genotyping with the standard panel of markers (Profiler kit), the 155 diandric triploid partial hydatidiform moles were dispermic in 150 (97%) and monospermic in 5 (3%). Using the expanded panel of markers (Identifiler kit) to further evaluate the five monospermic examples, three of these five were found to be dispermic. Thus, based on the combined analysis, 153 (99%) were dispermic (83 XXY, 57 XXX, 13 XYY) and 2 (1%) were monospermic (both XXX) ( Table 6 ). The three triandric tetraploid partial hydatidiform moles were at least dispermic (two XXYY, one XXXY).
All the 272 non-molar specimens had both p57 analysis and genotyping. Of the 272 non-molar specimens, 259 were p57-positive biparental diploid (Figures 3e-h and 9 ), 5 were p57-positive digynic triploid, 2 were p57-negative biparental diploid (uncertain etiology for loss of p57 expression as there were no morphological features of complete hydatidiform mole to suggest familial biparental hydatidiform mole), and 6 were p57-non-reactive (related to degenerative changes) biparental diploid. The digynic triploid cases were also analyzed with the expanded panel of markers (Identifiler kit) to enhance the strength of the data for establishing that there was no evidence of diandry (with an increased number of loci demonstrating triploidy with only shared alleles in double dosage (that is, no evidence of paternal alleles in double dosage), the chances of diandric triploidy become extremely small). Among the non-molar specimens, 11 trisomies were identified using the 9-marker panel, including 9 single trisomies involving chromosomes 2, 3, 4, 5 (2 cases), 7 (2 cases), and 13 (2 cases), and 2 double trisomies involving chromosome 4 and 7 and 7 and 13. It is worth noting that the nine-marker panel does not include markers for several of the chromosomes most commonly affected by trisomy in first trimester spontaneous abortions, including chromosomes 16, 18, 21, and 22; so many of those non-molar specimens with abnormal villous morphology potentially attributable to trisomies are not identified by this analysis. In 2 non-molar specimens subjected to analysis with the expanded 15-marker panel for academic interest, 2 additional trisomies were identified, including 1 single trisomy involving chromosome 21 and 1 double trisomy involving Figure 3 (a, b) . Partial hydatidiform mole displays an immature bulbous villous structure with trophoblastic hyperplasia on villous tips and slightly cellular myxoid stroma with small canalicular vessels, simulating an early complete hydatidiform mole (a). Villous stromal cells and cytotrophoblast are diffusely positive for p57 (b), arguing against a diagnosis of an early complete hydatidiform mole. Genotyping demonstrated diandric triploidy, confirming a diagnosis of partial hydatidiform mole (data not shown). (c, d). Partial hydatidiform mole displays an immature villous structure with mild trophoblastic hyperplasia on villous tips and cellular myxoid stroma with karyorrhectic nuclear debris, simulating an early complete hydatidiform mole (c). Villous stromal cells and cytotrophoblast are negative for p57 (d), usually supporting a diagnosis of an early complete hydatidiform mole; however, genotyping demonstrated diandric triploidy with androgenetic diploidy at chromosome 11 due to loss of the maternal copy (see Figure 8) . (e-g). Non-molar specimens with abnormal villous morphology demonstrate irregular villi with scalloped villous contours (e), mild trophoblastic hyperplasia (f) and trophoblastic inclusions (g), simulating a partial hydatidiform mole. Villous stromal cells and cytotrophoblast are positive for p57 in both the examples (f, h), consistent with either a non-molar specimen or a partial hydatidiform mole. Genotyping demonstrated biparental diploidy for both the examples, with other markers identifying trisomies as a potential explanation for the abnormal villous morphology (see Figure 9 ).
Diagnosis of hydatidiform moles chromosomes 16 and 21. Also for academic interest, further investigation of the non-molar specimen with double trisomy involving chromosomes 7 and 13 (which was initially interpreted as a partial hydatidiform mole by morphology) via singlenucleotide polymorphism array analysis identified triple trisomy of paternal origin involving chromosomes 7, 13, and 20. 42 There were 21 cases with more complex genotypes than those of typical molar and non-molar specimens. Of these, 14 were classifiable as forms of androgenetic/biparental mosaic specimens (11 of these are described in detail in our previous study). 44 These included six uniformly mosaic specimens characterized by villi that were hydropic but lacked trophoblastic hyperplasia and had discordant p57 expression in villous stromal cells and cytotrophoblast throughout (Figures 4a and b) . Genotyping demonstrated an excess of androgenetic alleles with variable paternal:maternal allele ratios Z2:1, indicating admixtures of androgenetic and biparental cell lines within individual villi (see previous study for genotyping example). 44 There were eight androgenetic/biparental mosaic specimens that had two distinct components within each case. One component was characterized by p57-discordant villi lacking trophoblastic hyperplasia and the other component was characterized by p57-negative villi with trophoblastic hyperplasia morphologically typical of a complete hydatidiform mole (Figures 4c-h ). Genotyping demonstrated an excess of androgenetic alleles with variable paternal:maternal allele ratios Z2:1 in the non-molar mosaic component and androgenetic diploidy in the molar component (when of sufficient size to allow for analysis of a pure region) (see previous study for genotyping example). 44 The remaining seven cases had problematic complex genotyping data and were not readily classifiable as any of the established diagnostic categories described above.
One particularly problematic case was encountered. It was a very early abortus characterized by immature chorionic villi with circumferential sheetlike trophoblastic hyperplasia, suggesting the possibility of an early complete hydatidiform mole; degenerative changes were also present, with some villi appearing necrotic. The p57 analysis was suboptimal and equivocal, with most villi appearing negative but some having very focal faint expression in the setting of focal yet suboptimal internal positive control expression in intermediate trophoblastic cells; this suboptimal result was also obtained on repetition of the assay and was likely related to the degenerative changes noted in the specimen. Genotyping demonstrated biparental diploidy, including informative results for the marker on chromosome 11 (location of the p57 gene). The combined findings were interpreted as equivocal for an early complete hydatidiform mole of familial biparental type versus an early abortus with trophoblastic hyperplasia, with a recommendation for some follow-up of the serum HCG level. Given the rarity of familial biparental hydatidiform moles, the potentially negative but suboptimal/equivocal p57 result, and the lack of available history of recurrent hydatidiform moles or ancillary genetic testing to identify any of the known mutations associated with this disorder, we could not establish a definitive diagnosis of a familial biparental hydatidiform mole for this case.
Discussion
The current study of a large prospective series of potentially molar products of conception specimens analyzed with p57 immunohistochemistry and short tandem repeat genotyping provides a comprehensive summary of the characteristics of molar and non-molar specimens assessed with these techniques. Both p57 analysis and genotyping can be successfully performed in a high proportion of cases (96-98%), even when specimens are derived from a variety of outside laboratories (86% consultation cases) with likely variable specimen fixation times/ processing methods from laboratory to laboratory. These techniques thereby allow for definitive classification of a high proportion of those cases with successful ancillary testing results (99%).
In the current study, a substantial proportion of the cases (86%) was derived from our gynecologic pathology consultation service, so we acknowledge some degree of bias in this study set. Despite this, the set included a wide morphological spectrum of Diagnosis of hydatidiform moles cases, ranging from typical complete hydatidiform moles and partial hydatidiform moles with characteristic diagnostic features (including complete hydatidiform moles with prominent trophoblastic hyperplasia and invasive complete hydatidiform moles in hysterectomy specimens) to typical early complete hydatidiform moles, to subtle forms of complete hydatidiform moles and partial hydatidiform moles, as well as non-molar specimens with a spectrum of appearances. Interestingly, this prospectively collected set has had since its beginning both a substantial number of hydatidiform moles (55% of the total cases in the current study set) and a greater proportion of complete hydatidiform moles than partial hydatidiform moles (complete hydatidiform mole:partial hydatidiform mole ratio ¼ 1.3 in the current study set). This has been a surprise to us, given that diagnosis of partial hydatidiform moles and non-molar specimens is more problematic than complete hydatidiform moles and one would expect partial hydatidiform moles to outnumber complete hydatidiform moles in a set of consultation cases. Although early forms are expected to constitute a notable subset of complete hydatidiform moles (given that a substantial number of hydatidiform moles are encountered at relatively early gestational ages since the introduction of routine imaging studies early in pregnancy), they did not constitute the exclusive form of complete hydatidiform mole represented in this set (as judged by subjective morphological assessment, as genotyping is identical for all forms of complete hydatidiform moles). Thus, we believe the study set is comprised of a wide spectrum of cases, including a sufficient number of complete hydatidiform moles, suggesting that the database is not unduly biased.
One interesting finding in this series was the observation that all cases encountered in women aged 446 years were complete hydatidiform moles (that is, none were partial hydatidiform moles or non-molar specimens). This distinct predilection toward complete hydatidiform mole over partial hydatidiform mole in women over a particular age has been observed in previous studies. 45, 46 We did not have specific data on the menopausal status of the older women in our study but of the 22 patients aged 446 years who had complete hydatidiform moles (age range ¼ 47-55), 8 were aged Z52 years and 11 were aged Z50 years, indicating that many of these women were likely perimenopausal and that some were probably postmenopausal. Although uncommon, examples of complete hydatidiform moles in postmenopausal women ranging in age from 51 to 61 years have been reported. 47, 48 This large series demonstrates that complete hydatidiform moles are virtually always p57-negative, with only rare examples (0.5%) displaying aberrant (positive) p57 expression, attributable to Modern Pathology (2014) 27, 238-254
Diagnosis of hydatidiform moles attributable to the loss of the maternal copy of chromosome 11. 50 Partial hydatidiform moles are also almost always diandric triploid conceptions (98%), with nearly all being dispermic (99%). The rarity of monospermic partial hydatidiform moles observed in our study is similar to results reported in a recent study. 51 Rare partial hydatidiform moles (2%) are triandric tetraploid. 52 The rare examples of both complete hydatidiform moles and partial hydatidiform moles with aberrant p57 expression can be correctly classified by genotyping. These aberrant cases present an interesting problem for classification of hydatidiform moles. The p57-negative partial hydatidiform moles would have been interpreted as complete hydatidiform moles based on the p57 result if genotyping had not been performed on these cases. The distinction of a partial hydatidiform mole from a complete hydatidiform mole is important, because the risk of persistent gestational trophoblastic disease differs for these entities, being significantly higher for complete hydatidiform moles (15-20%) than for partial hydatidiform moles (0.2-4%). [1] [2] [3] [4] Potential 'over-diagnosis' as a complete hydatidiform mole is without significant clinical consequence, as appropriate follow-up with serum HCG levels would occur, perhaps for a longer time than if diagnosed as a partial hydatidiform mole, but there would be little harm in opting for that more conservative (safe) approach other than possibly requiring contraception for a somewhat longer period. However, 'under-diagnosis' of a complete hydatidiform mole with aberrant retained p57 expression as a partial hydatidiform mole using only p57 immunohistochemistry without molecular genotyping would underestimate the potential risk of persistent gestational trophoblastic disease and could lead to insufficient clinical evaluation and follow-up. Our study establishes that immunohistochemical analysis of p57 expression is highly correlated with genotyping results. Only 3 of the 359 hydatidiform moles (0.8%) had aberrant p57 expression (that is, contrary to the expected result for the diagnostic category). In conjunction with previous results demonstrating the high reproducibility (kappa value of 0.9) of interpretation of p57 immunostains, 14, 15 the findings demonstrate that p57 immunohistochemistry is extremely reliable for diagnosis of complete hydatidiform moles. Thus, the algorithmic approach for diagnosis of hydatidiform moles we advocate that uses p57 results to triage cases for genotyping ( Figure 1 ) provides a highly reliable method for accurate diagnosis of complete hydatidiform moles in routine practice using a single immunohistochemical stain, with very little risk of misclassification of complete hydatidiform moles. Consequently, genotyping of complete hydatidiform moles is not necessary in routine practice and can be reserved for problematic cases, such as when p57 immunostaining is suboptimal or unsatisfactory or when morphology and p57 results appear discrepant (as in the p57-positive complete hydatidiform mole shown in Figures 2c and d) . One exceptional situation would be in the case of recurrent hydatidiform moles, which raises the possibility of familial biparental hydatidiform mole. This is a pure maternal-effect recessive inherited disorder attributable to mutations of NLRP7 or C6orf221, resulting in a multi-locus epigenetic defect with failure to establish maternal identity at imprinted loci and abnormal expression of imprinted genes. [53] [54] [55] [56] [57] [58] [59] [60] [61] Patients with this disorder can have multiple/recurrent complete hydatidiform moles that are morphologically, immunophenotypically, and clinically similar to conventional complete hydatidiform moles, that is, they are p57-negative and appear to have a similar risk of persistent gestational Only two cases in our study had the combination of a p57-negative result and biparental diploidy; these did not have any morphology features to suggest a complete hydatidiform mole. Another case with a negative p57 result and unsatisfactory genotyping was quite immature and also lacked any diagnostic features of a complete hydatidiform mole. It is possible these non-molar appearing cases had some genetic or epigenetic alteration affecting p57, leading to a lack of p57 expression. The one early abortus with circumferential trophoblastic hyperplasia, equivocal/ suboptimal p57 result, and biparental diploidy per genotyping might be an example of a familial biparental early complete hydatidiform mole; however, there was no known history of recurrent hydatidiform moles or known subsequent ancillary genetic testing to confirm that disorder. Thus, only one potential familial biparental hydatidiform mole was encountered in our study. The findings in our study also confirm that p57 immunohistochemical analysis is quite useful for recognition of androgenetic/biparental mosaic/ chimeric conceptions, 24 as discussed in detail in our recent study. 44 These include uniformly androgenetic/biparental mosaic specimens without molar features (probably early forms of placental mesenchymal dysplasia, which is characterized by androgenetic/biparental mosaicism and lack of trophoblastic hyperplasia), 62 androgenetic/ biparental mosaic specimens with a molar component (typically complete hydatidiform mole), and twin gestations comprised of complete hydatidiform mole and non-molar specimen components. Recognition of the discordant and divergent staining patterns in these specimens is the key to correct interpretation of these complex specimens and is necessary for specific microdissection of the different components to assure accurate molecular genotyping. 44 As discussed in our previous reproducibility studies, 14 ,15 the use of the algorithmic approach we advocate represents a compromise between traditional morphological assessment, which has limitations, and genotyping of all cases, which is clearly more costly. As demonstrated herein, the p57 component of the algorithm captures essentially all complete hydatidiform moles, the most important group to readily identify for clinical management purposes. This analysis can be performed in most immunohistochemistry laboratories without the need for highly specialized equipment and expertise, such as that required for genotyping. Genotyping of all p57-positive potentially molar specimens per the algorithm provides for definitive diagnosis of virtually all partial hydatidiform moles and non-molar specimens, allowing for refined management of these entities. However, in the setting of limited resources, use of ancillary techniques can be focused on identifying the entity with the greatest risk for persistent gestational trophoblastic disease, namely complete hydatidiform moles, by selectively applying only p57 immunohistochemistry to assist in diagnosing complete hydatidiform moles and foregoing genotyping for distinction of partial hydatidiform moles from non-molar specimens. For the latter situation, an equivocal diagnosis, such as 'abnormal villous morphology, partial hydatidiform mole cannot be excluded', might need to be rendered. As the risk of persistent gestational trophoblastic disease for partial hydatidiform moles is much closer to that of non-molar specimens than complete hydatidiform moles, this may well be acceptable for routine practice, with the understanding that an equivocal diagnosis will potentially lead to clinical management as a partial hydatidiform mole at least for some abbreviated time frame, and that this approach does have accompanying costs (clinic visit, multiple serum beta-HCG levels, contraception), which might well rival the cost of genotyping. It is also worth noting that an apparently unequivocal diagnosis of either partial hydatidiform mole or non-molar specimen established on the basis of morphological assessment alone is not guaranteed to be accurate even when rendered by an experienced gynecologic pathologist. Therefore, the most ideal method of correctly classifying all hydatidiform moles and non-molar specimens is a combined approach including correlation of morphological features, p57 immunohistochemistry, and molecular genotyping. In investigational pursuits, all molar specimens should be evaluated with ancillary techniques to assure rigorous classification of cases, particularly when designed to ascertain risk of persistent gestational trophoblastic disease associated with the various subtypes of hydatidiform moles.
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